Trials / Completed
CompletedNCT00135304
ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism
ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism: A Comparison of Sensipar® and Low Dose Vitamin D vs. Escalating Doses of Vitamin D Alone
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 170 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the proportion of chronic kidney disease (CKD) subjects on dialysis receiving Sensipar® and low dose vitamin D or escalating doses of vitamin D alone who are able to achieve the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI) secondary hyperparathyroidism (HPT) treatment targets for both biointact parathyroid hormone (biPTH) and calcium-phosphorus (Ca x P) product.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sensipar® | Cinacalcet hydrochloride |
| DRUG | Vitamin D | Vitamin D administered IV |
Timeline
- Start date
- 2005-08-01
- Primary completion
- 2006-10-01
- Completion
- 2006-12-01
- First posted
- 2005-08-26
- Last updated
- 2014-02-11
Source: ClinicalTrials.gov record NCT00135304. Inclusion in this directory is not an endorsement.